Alembic Pharmaceuticals announced that it has received final approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate tablets USP, 54 mg and 160 mg. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Tricor tablets, 54 mg and 160 mg of AbbVie Inc.